Oxis International Inc. Receives GRAS Status for Its Patented L-Ergothioneine Anti-Oxidant
Oxis International Inc.
10.10.2011 09:30
---------------------------------------------------------------------------
Report Clears Path for Oxis to Develop Full Line of Dietary Supplements,
Functional Foods and Beverages, and Personal Care Products
BEVERLY HILLS, Calif., 2011-10-10 09:30 CEST (GLOBE NEWSWIRE) --
Oxis International Inc. (OTCBB:OXIS) (Euronext:OXI.PA) today announced that an
independent scientific panel of experts has certified the GRAS (Generally
Recognized as Safe) status of its patented anti-oxidant L-ergothioneine.
There are over 100 scientific papers, published in peer review journals
describing the significant anti-oxidative effects of L-ergothioneine. Leading
scientific experts, including Dr. Bruce Ames, have stated that l-ergothioneine
may well be essential to human life because of the unique and critical role
that it plays in the body's anti-oxidant defense system. In fact, the body has
a specific gene to produce an ergothioneine transporter. In addition to its
highly published general anti-oxidative effects, L-ergothioneine has shown
specific promise in extending healthy lifespans, cognitive function, and lung
and heart health. With its introduction of ErgoFlex(tm), Oxis is the only company
in the world offering dietary supplement products containing pure
L-ergothioneine.
David Saloff, CEO of Oxis stated, 'Achieving GRAS status for our
L-ergothioneine opens the door wide to significant new commercial opportunities
for the Company including the multi-billion dollar market segment for
functional foods and beverages. This is in addition to the company's plans to
develop a proprietary line of personal care products where L-ergothioneine is
already considered one of the real scientifically based breakthrough anti-aging
ingredients. Based upon the extensive body of scientific and safety data for
L-ergothioneine, Oxis will now move ahead to establish a leadership role in the
rapidly growing global market for health and wellness products.'
Following a comprehensive review of the safety, toxicology and proposed usage,
an independent panel of experts reached a unanimous decision that Oxis' pure,
synthetic L-ergothioneine, produced using the patented Oxis manufacturing
method is safe for use in dietary supplements, food and beverage products. GRAS
is a US Food and Drug Administration (FDA) designation that an ingredient that
may be added to food is considered safe by experts.
Oxis International, Inc. is engaged in the research, development and
distribution of 'natural' products that counteract the harmful effects of
physiological stress and aging.
(www.oxis.com)
Oxis International, 468 N. Camden Drive, Beverly Hills Ca. 90210 - Phone
424-248 2300.
CONTACT: David Saloff - CEO 424-248 2300
Michael Handelman - CFO 424-248 2300
News Source: NASDAQ OMX
10.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Oxis International Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6918294025
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Oxis International Inc.
10.10.2011 09:30
---------------------------------------------------------------------------
Report Clears Path for Oxis to Develop Full Line of Dietary Supplements,
Functional Foods and Beverages, and Personal Care Products
BEVERLY HILLS, Calif., 2011-10-10 09:30 CEST (GLOBE NEWSWIRE) --
Oxis International Inc. (OTCBB:OXIS) (Euronext:OXI.PA) today announced that an
independent scientific panel of experts has certified the GRAS (Generally
Recognized as Safe) status of its patented anti-oxidant L-ergothioneine.
There are over 100 scientific papers, published in peer review journals
describing the significant anti-oxidative effects of L-ergothioneine. Leading
scientific experts, including Dr. Bruce Ames, have stated that l-ergothioneine
may well be essential to human life because of the unique and critical role
that it plays in the body's anti-oxidant defense system. In fact, the body has
a specific gene to produce an ergothioneine transporter. In addition to its
highly published general anti-oxidative effects, L-ergothioneine has shown
specific promise in extending healthy lifespans, cognitive function, and lung
and heart health. With its introduction of ErgoFlex(tm), Oxis is the only company
in the world offering dietary supplement products containing pure
L-ergothioneine.
David Saloff, CEO of Oxis stated, 'Achieving GRAS status for our
L-ergothioneine opens the door wide to significant new commercial opportunities
for the Company including the multi-billion dollar market segment for
functional foods and beverages. This is in addition to the company's plans to
develop a proprietary line of personal care products where L-ergothioneine is
already considered one of the real scientifically based breakthrough anti-aging
ingredients. Based upon the extensive body of scientific and safety data for
L-ergothioneine, Oxis will now move ahead to establish a leadership role in the
rapidly growing global market for health and wellness products.'
Following a comprehensive review of the safety, toxicology and proposed usage,
an independent panel of experts reached a unanimous decision that Oxis' pure,
synthetic L-ergothioneine, produced using the patented Oxis manufacturing
method is safe for use in dietary supplements, food and beverage products. GRAS
is a US Food and Drug Administration (FDA) designation that an ingredient that
may be added to food is considered safe by experts.
Oxis International, Inc. is engaged in the research, development and
distribution of 'natural' products that counteract the harmful effects of
physiological stress and aging.
(www.oxis.com)
Oxis International, 468 N. Camden Drive, Beverly Hills Ca. 90210 - Phone
424-248 2300.
CONTACT: David Saloff - CEO 424-248 2300
Michael Handelman - CFO 424-248 2300
News Source: NASDAQ OMX
10.10.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Oxis International Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6918294025
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------